The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.
Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.
Hemophilia Market Trends:
The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market. Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment and therapy.
Breakup by Type:
Hemophilia A represents the largest market segment due to the rising prevalence of hemophilia A among individuals across the globe and the increasing requirement for patient care.
Breakup by Treatment:
On-demand treatment currently holds the largest market share as it is highly beneficial for patients with mild or moderate hemophilia who bleed less often.
Breakup by Therapy:
Replacement therapy is a standard therapy used to treat hemophilia as it helps replace the missing clotting factor among patients. It involves offering the missing clotting factor to patients from an external source.
Breakup by Region:
Middle East and Africa
North America exhibits a clear dominance in the market due to the increasing government spending on healthcare and research and development (R&D) activities, along with the presence of various leading players in the country.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Base Year of the Analysis
Type, Treatment, Therapy, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global hemophilia market was valued at US$ 11.7 Billion in 2022.
We expect the global hemophilia market to exhibit a CAGR of 11.1% during 2023-2028.
The rising prevalence of genetic abnormalities, along with the increasing consumer awareness towards numerous benefits of following appropriate procedures to facilitate the early screening of neonates, is primarily driving the global hemophilia market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective hemophilia treatment procedures across several nations to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.
Based on the type, the global hemophilia market can be categorized into hemophilia A, hemophilia B, hemophilia C, and others. Currently, hemophilia A accounts for the majority of the global market share.
Based on the treatment, the global hemophilia market has been segregated into on-demand and prophylaxis, where on-demand currently exhibits a clear dominance in the market.
Based on the therapy, the global hemophilia market can be bifurcated into replacement therapy, ITI therapy, and gene therapy. Currently, replacement therapy holds the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global hemophilia market include Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.